New CRISPR breakthrough promises more affordable disease diagnostics
A team at the University of Florida developed a DNA-guided CRISPR system published in *Nature Biotechnology* that improves precision, reduces costs, and minimizes off-target effects for disease diagnostics and treatments. The breakthrough allows RNA targeting without altering DNA, enabling safer real-time corrections for conditions like cancer and early detection of viruses such as HIV with 100% accuracy for hepatitis C.
Researchers at the University of Florida have created a new CRISPR technology that uses DNA instead of RNA to guide gene-editing enzymes, marking a shift from decades of conventional practice. Published in *Nature Biotechnology*, the system targets RNA—working copies of DNA—without permanently altering the genetic code, reducing unintended effects by orders of magnitude while lowering costs. Led by Piyush Jain, an associate professor in chemical engineering, the team demonstrated the system’s ability to correct faulty RNA instructions in real time, offering a safer approach for therapies. Unlike RNA-based CRISPR tools, which degrade quickly and risk off-target impacts, DNA guides are more stable and precise, making them ideal for clinical diagnostics. The technology also enables early detection of diseases like HIV and hepatitis C with high accuracy, potentially improving patient outcomes. Co-first authors Carlos Orosco, Boyu Huang, and Santosh Rananaware contributed to the project, which required rethinking traditional CRISPR methods. Beyond diagnostics, the researchers envision applications in organ transplantation and disease study. The breakthrough could expand access to CRISPR-based tools by reducing manufacturing costs and improving stability, paving the way for broader clinical and research use.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.